17 results about "Epstein bar virus" patented technology

Herpesviridae glycoprotein B (gB) polypeptides comprising a modified ectodomain is stabilized in the prefusion state, enabling development of inhibitors and vaccines directed against these viral pathogens. Modifications to DI, DII, and DV subdomains are important to stabilization of gB in the prefusion state, and additional modifications result in a further improved stabilization of gB in the prefusion state. The gB can be derived from an Epstein Barr Virus (EBV), a Human Cytomegalovirus (CMV), a Human Herpesvirus 6 (HHV6), a Herpes Simplex Virus 1 (HSV1), or a Varicella Zoster Virus (VZV). Polypeptides, nucleic acid constructs, compositions, and methods of using same to elicit an immune response are described.

This disclosure concerns methods of analysing and sequencing viral genomic DNA, in particular Epstein-Barr virus (EBV) genomic DNA, using viral-specific nucleic acid capture probes and long read sequencing.

The present disclosure provides antibodies, and antigen binding fragments thereof, which bind an extracellular domain region of an Epstein-Barr virus (EBV) membrane protein, and related nucleic acids, vectors, pharmaceutical compositions, cells, and methods of use thereof. The antibodies, and antigen binding fragments thereof, as described herein can find utility as therapeutic and diagnostic agents for EBV infections and EBV-mediated diseases or as research agents.

The present application describes T cell receptors specifically binding tumor antigen derived peptides, especially derived from Mitogen-Activated Protein Kinase 8 Interacting Protein 2 (MAPK8IP2), Epstein-Barr Virus (EBV) proteins or Human Endogenous Retrovirus (HERV), as well as engineered T cells expressing these receptors, nucleic acids encoding these T cell receptors and methods of using T cells expressing these engineered T cells in adoptive cell transfer to treat diseases in a subject.

The present disclosure relates to nucleic acid molecules (e.g., self-replicating RNAs (srRNAs) expressing one or more antigenic determinants derived from Epstein-Barr virus (EBV)), recombinant cells containing the nucleic acid molecules and pharmaceutical compositions, and uses of such srRNA molecules, recombinant cells and compositions for eliciting pharmacodynamic effects in a subject. Methods for preventing and / or treating a variety of health conditions associated with EBV infection are also provided.

We have generated a 3D model of the glycoprotein B (gB) of Epstein-Barr virus (EBV) to design candidate stabilizing mutations that increase the stability of the prefusion state essential for an effective EBV gB based vaccine. Provided herein are engineered polypeptides derived from the EBV gB, which include an altered EBV gB ectodomain that has modifications relative to the native EBV gB ectodomain that stabilize a prefusion conformation of the polypeptides. In various aspects, the modifications are amino acid substitutions to generate pairs of cysteine amino acid residues, preferably positioned to connect different domains of the poly peptide or different copies of the polypeptide in a trimeric or multimeric conformation via formation of disulfide bonds during protein expression. In additional aspects, the modifications and / or the engineered polypeptides do not contain pairs of cysteine amino acid residues that may form disulfide bonds in a postfusion conformation.

The present invention relates, inter alia, to a composition comprising the BILF2 glycoprotein of Epstein-Barr-Virus (EBV), a nucleic acid encoding the BILF2 glycoprotein of EBV, or an extracellular vesicle (EV) or EB-virus-like particle (VLP) displaying at its surface the BILF2 glycoprotein of EBV, for use in a method of eliciting antibodies against said BILF2 glycoprotein which reduce infectivity of EBV for human epithelial cells. Preferably, said composition elicits antibodies that prevent infection of human epithelial cells by EBV.

Reconstructed Modified Vaccinia Ankara (rMVA) vectors configured to encode stable Epstein Bar Virus (EBV) glycoproteins gp42, gL, gH, gp350, and gB, compositions comprising the rMVA vectors, vaccines comprising the compositions, and methods of preventing EBV infection by administering the vaccines and eliciting an innate and humoral immune response.

Provided herein are engineered Epstein-Barr virus (EBV) polypeptides, polynucleotides encoding the same, related vectors and vaccine compositions, and related methods of making and using said compositions. The compositions disclosed herein may be useful for vaccination against EBV.

In particular, synthetic mRNA is provided that can specifically induce transcription of one or more Epstein-Barr virus (EBV) lysis genes in an EBV infected cell, thereby destroying the cell. Also described herein are methods of synthesizing the mRNA and methods of using the mRNA for the treatment of EBV-related diseases, such as EBV-positive cancer.

The present disclosure provides methods and compositions of modified oligonucleotide primer and probe combinations, structurally modified with locked nucleic acids, quenchers, and dyes, effective to detect tumor-derived Human Papilloma Virus (HPV) and tumor-derived Epstein-Barr virus (EBV) and, especially, to distinguish viral DNA derived from tumors from viral DNA derived from infectious viral particles.

An isolated trifunctional bispecific antibody for use in a method of treating a patient suffering from a disease and / or disorder associated with reactivation of Epstein-Barr virus (EBV) in at least B cells and potentially other susceptible cells, such as susceptible epithelial cells, the method comprising: providing an autologous cell preparation of enriched B cells of the patient; incubating the enriched B cells with a trifunctional bispecific antibody for a period of time sufficient to establish a physical interaction between the trifunctional bispecific antibody and the enriched B cells to obtain an incubation mixture; transferring the incubation mixture obtained after incubation into the same patient, wherein the trifunctional bispecific antibody comprises: (a) a first binding arm binding to B cells via a B cell surface antigen; (b) a second binding arm binding to T cells via a T cell surface antigen; (c) an Fc part binding to Fc receptor positive cells. The invention also discloses a pharmaceutical composition comprising the isolated trifunctional bispecific antibody for use in treating a patient suffering from a disease and / or disorder associated with reactivation of EBV in B cells, and an ex vivo method for the preparation of the pharmaceutical composition.

The present invention relates to modified immune cells expressing T cell receptors (TCR) targeting Epstein-Barr virus (EBV) and their pharmaceutical uses. The present invention provides compositions comprising LMP2A specific TCR-T cell populations for the treatment of EBV-associated cancers and other indications, as well as methods for preparing and using the compositions. The present invention also provides nucleic acid sequences encoding the TCR and vectors thereof. The modified EBV-targeting immune cells of the present invention are activated upon binding tumor cells; they recognize targets and activate T-cell functions depending on presentation by major histocompatibility complex (MHC) molecules, while maintaining proliferation and antitumor activity. The EBV-targeting immune cells have demonstrated favorable antitumor efficacy in preclinical studies, offering a novel therapeutic strategy for patients with EBV-associated cancers.

Provided herein are compositions comprising isolated T cells specific for one or more viral antigens derived from viruses such as adenovirus (ADV), cytomegalovirus (CMV), BK virus (BKV), Epstein-Barr virus (EBV), human herpes virus 6 (HHV6), John Cunningham virus (JC), or human immunodeficiency virus (HIV), methods for obtaining them, libraries including them, and uses thereof in treating viral infections.

The present disclosure relates to nucleic acids molecules, e.g., self-replicating RNA (srRNA) expressing antigenic determinant(s) derived from Epstein-Barr virus (EBV), recombinant cells and pharmaceutical compositions containing the same, as well as the use of such srRNA molecules, recombinant cells, and compositions for eliciting a pharmacodynamic effect in a subject. Also provided are methods for preventing and / or treating various health conditions associated with EBV infection.

Provided herein are methods, systems, and computer readable medium for detecting nucleic acid from a pathogen, e.g., virus, e.g., Epstein-Barr virus (EBV), in a cell-free nucleic sample from an individual at risk of a condition, e.g., nasopharyngeal carcinoma (NPC). The methods, systems, and computer readable medium can be used to screen for the presence of the condition, e.g., NPC, using thresholds adjusted based on sample attributes.

Disclosed herein are methods for generating / expanding a population of immune cells comprising immune cells specific for Epstein-Barr virus (EBV) lytic antigens, the methods comprising stimulating immune cells specific for EBV lytic antigens by contacting peripheral blood mononuclear cells (PBMCs) with (i) one or more peptides corresponding to all or a portion of one or more EBV lytic antigens; or (ii) antigen presenting cells (APCs) presenting one or more peptides corresponding to all or a portion of one or more EBV lytic antigens. Also disclosed are populations of immune cells comprising immune cells specific for EBV lytic antigens expanded according to these methods, and uses thereof.